Carl Kohrt, vice president and general manager of Eastman Kodak'sHealth Sciences division, has found himself in privileged companyat the Rochester, NY, film giant. Kohrt joined chief executiveGeorge Fisher as one of three executives named to a new
Carl Kohrt, vice president and general manager of Eastman Kodak'sHealth Sciences division, has found himself in privileged companyat the Rochester, NY, film giant. Kohrt joined chief executiveGeorge Fisher as one of three executives named to a new chiefoperating office designed be the nucleus of Kodak's senior managementteam.
In announcing the moves last week, Fisher said the new teamwould handle the day-to-day operations of Kodak's global business.All the business, manufacturing, R&D and geographic regionsthat previously reported to other executives will report to thenew office. Kohrt will remain head of the Health Sciences unit.
Fisher will add COO to his titles of chairman, president andCEO, while Kohrt adds executive vice president and assistant COOto his resume. Joining Fisher and Kohrt on the team is DanielCarp, vice president and general manager of Kodak's European,African and Middle Eastern region.
Kodak said the moves were being made to strengthen the nextgeneration of Kodak's management team, making Kohrt and Carp automaticfront-runners in the event Fisher leaves the company.
Fisher was named to lead Kodak in 1993 and has dramaticallyincreased the company's focus on digital imaging (SCAN 4/12/94).He has said he intends to remain with the company at least throughhis current contract, which runs until 1998.
Kohrt, a 24-year Kodak veteran who has headed Health Sciencesfor four years, has led the division to increased worldwide marketshare despite an era of dramatic change and consolidation, Fishersaid.
"Carl Kohrt has defined Kodak's leadership in one of themost challenging markets in the world today, health care,"Fisher said.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.